Cite

HARVARD Citation

    Khan, F. et al. (2014). Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO‐incompatible haematopoietic stem cell transplantation. Transfusion medicine. 24 (3), pp. 187-188. [Online]. 
  
Back to record